

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1)\***

**PIERIS PHARMACEUTICALS, INC.**

---

(Name of Issuer)

**Common Stock**

---

(Title of Class of Securities)

**720795103**

---

(CUSIP Number)

**December 31, 2016**

---

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

|   |   |                               |
|---|---|-------------------------------|
| <b>1.</b>   | NAMES OF REPORTING PERSONS<br>Novo Nordisk A/S  |                               |
| <b>2.</b>   | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*<br><br>(a) <input type="radio"/><br>(b) <input type="radio"/> |                               |
| <b>3.</b>   | SEC USE ONLY  |                               |
| <b>4.</b>   | CITIZENSHIP OR PLACE OF ORGANIZATION<br>The Kingdom of Denmark  |                               |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON WITH | <b>5.</b>   | SOLE VOTING POWER<br>0        |
|   | <b>6.</b>   | SHARED VOTING POWER<br>0      |
|   | <b>7.</b>   | SOLE DISPOSITIVE POWER<br>0   |
|   | <b>8.</b>   | SHARED DISPOSITIVE POWER<br>0 |
| <b>9.</b>   | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>0   |                               |
| <b>10.</b>  | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*<br><br><input type="radio"/>              |                               |
| <b>11.</b>  | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>0%   |                               |
| <b>12.</b>  | TYPE OF REPORTING PERSON*<br>CO   |                               |

**Item 1(a). Name of Issuer:**

Pieris Pharmaceuticals, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**

Lise-Meitner-Strasse 30

85354 Freising-Weihenstephan

Germany

**Item 2(a). Name of Person Filing:**

Novo Nordisk A/S

**Item 2(b). Address of Principal Business Office or, if None, Residence:**

Novo Allé

DK – 2880, Bagsvaerd

Denmark

**Item 2(c). Citizenship:**

The Kingdom of Demark

**Item 2(d). Title of Class of Securities:**

Common Stock

**Item 2(e). CUSIP Number:**

720795103

**Item 3. If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:**

- (a)  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
- (k)  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership.**

Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

- (a) Amount beneficially owned: 0
- (b) Percent of class: 0%
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or to direct the vote: See item 5 of cover page.
  - (ii) Shared power to vote or to direct the vote: See item 6 of cover page.
  - (iii) Sole power to dispose or to direct the disposition of: See item 7 of cover page.
  - (iv) Shared power to dispose or to direct the disposition of: See item 8 of cover page.

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

**Item 10. Certifications.**

Not applicable.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

January 25, 2017

\_\_\_\_\_  
(Date)

/s/ Jesper Brandgaard

\_\_\_\_\_  
(Signature)

Jesper Brandgaard, Chief Financial Officer

\_\_\_\_\_  
(Name/Title)